Orally Disintegrating Tablet

Aricept Evess®

Donepezil HCl Orodispersible tablets 5mg, 10mg

Aricept Evess® tablets are indicated for the treatment of MILD, MODERATE and SEVERE dementia in Alzheimer's Disease.

EARLIER

Earlier intervention preserves more function[1-3]

HIGHER

Higher the dose, better the response[4-6]

LONGER

Longer the duration of treatment, better the long-term outcome[7-8]

BETTER

Better efficacy across all of the Alzheimer's Disease domains such as cognition, global function, neuropsychiatry symptoms and quality of life[9-10]

References:
1. B. Dubois et al. Alzheimer's & Dementia (2014) 1-9. **2.** Winblad B et al. Dement Geriatr Cogn Disord 2006;21:353–63. **3.** Seltzer B et al. Arch Neurol. 2004;61:852-1856. **4.** Homma A. et al. Dement Geriatr Cogn Disord 2008;25:399-407. **5.** Farlow MR, et al. Clin Ther. 2010; 32: 1234–51. **6.** Whitehead A et al. Int J Geriatr Psychiatry 2004;19:624-633. **7.**Olazaran J, et al. Dement Geriatr Cogn Disord Extra 2013;3:48-59. **8.** Howard R, et al. New Engl J Med 2012;366:893-903. **9.** Cummings J et al. CNS Neurosci Ther. 2016 Mar;22(3):159-66. **10.** Lee et al. Acta Neurol Scand. 2015 May;131(5):259-67.

ABBREVIATED PRESCRIBING INFORMATION

Composition: Each tablet contains 5/10mg donepezil hydrochloride equivalent to 4.56mg/9.12mg donepezil free base. **Indication:** ARICEPT® EVESS tablets are indicated for the treatment of mild, moderate, and severe dementia in Alzheimer's Disease. **Dose and administration:** ***Adults/elderly:*** Treatment is initiated at 5mg/day (once-a-day dosing). ARICEPT® EVESS should be taken orally, in the evening, just prior to retiring. The tablet should be placed on the tongue and allowed to disintegrate before swallowing with or without water, according to patient preference. The 5mg/day dose should be maintained for at least one month in order to allow the earliest clinical responses to treatment to be assessed and to allow steady-state concentrations of donepezil hydrochloride to be achieved. Following a 4-6 weeks of clinical assessment in patients who tolerated treatment at 5mg/day, the dose of ARICEPT® EVESS can be increased to 10mg/day (once-a-day dosing). ***Renal and hepatic impairment:*** A similar dose schedule can be followed for patients with renal impairment as clearance of donepezil hydrochloride is not affected by this condition. ***Children:*** Not recommended. ***Contra-indication:*** ARICEPT® EVESS is contraindicated in patients with a known hypersensitivity to donepezil hydrochloride, piperidine derivatives, or to any excipients used in the formulation. **Special Warnings and precautions for use:** ***Undesirable effects:*** The most common adverse events (incidence ≥ 5% and twice the frequency of placebo in patients receiving 10mg/day) were diarrhea, muscle cramps, fatigue, nausea, vomiting and insomnia. **Special precautions for storage:** Do not store above 30°C. Tablets may change color with light, so keep in aluminium pouch until taken.

For Healthcare Professionals only.
For further information and full prescribing information please contact:

Eisai (Malaysia) Sdn. Bhd. (18039-D)
Unit 701D, Level 7, Tower D, Uptown 5 Damansara Uptown,
No. 5, Jalan SS21/39, 47400 Petaling Jaya, Selangor, Malaysia
Tel: +603-7732 0380Fax: +603-7732 0390

human health care

ML-AE-TY-22G-01